Oregon to receive $3.8M settlement from GlaxoSmithKline case

Oregon to receive $3.8M settlement from GlaxoSmithKline case

The state will receive $3.8 million under a multi-state settlement after the drug firm was accused of improperly marketing three pharmaceutical products.

The Oregon Department of Justice and its counterpart in Illinois spearheaded a lawsuit accusing GSK of marketing the drug Advair for mild asthma through 2010, though it had only been approved for moderate to severe cases due to risks of the drug.

The suit also accused the firm of improperly marketing two other drugs between 1999 and 2003. It said the firm deceptively promoted the antidepressant Paxil as safe for children and adolescents when it was not approved, raising concerns of increased suicide risk. It said GSK improperly promoted another antidepressant, Wellbutrin, for weight loss and sexual dysfunction though it was never approved for those things.

Read more at OregonLive.com